Morgan Stanley has revised its price target for Abbott Laboratories (ABT, Financial), increasing it from $117 to $127 per share. The financial firm maintains an Equal Weight rating on the stock, reflecting a balanced outlook.
Despite broader economic uncertainties, Abbott appears to be navigating the market landscape with confidence. The analyst highlighted the company's strong defensive position and strategic flexibility as key strengths. However, it is noted that these advantages may already be reflected in Abbott's positive stock performance since the beginning of the year, as well as in its current premium valuation.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 23 analysts, the average target price for Abbott Laboratories (ABT, Financial) is $140.41 with a high estimate of $158.00 and a low estimate of $111.34. The average target implies an upside of 8.25% from the current price of $129.70. More detailed estimate data can be found on the Abbott Laboratories (ABT) Forecast page.
Based on the consensus recommendation from 28 brokerage firms, Abbott Laboratories's (ABT, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Abbott Laboratories (ABT, Financial) in one year is $118.41, suggesting a downside of 8.7% from the current price of $129.7. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Abbott Laboratories (ABT) Summary page.
